Results 1 to 10 of about 98,340 (384)

Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations

International Journal of General Medicine, 2020
Background One of the major challenges in pediatric treatment is the lack of suitable drug preparations specifically designed and marketed for children.
A. Belayneh, E. Tadese, F. Molla
semanticscholar   +1 more source

Iowa Developments, April 2003, Vol.12, no.2 [PDF]

, 2003
Resource to help educate businesses or communities about state-sponsored ...

core  

Development, qualification, and application of a highly efficient and robust new peak detection workflow for the LC-MS peptide mapping multi-attribute method

mAbs
The multi-attribute method (MAM) by liquid chromatography-mass spectrometry peptide mapping has the potential to replace multiple conventional HPLC- and capillary electrophoresis-based purity/impurity assays for release and stability testing of protein ...
Thomas Pohl, Patrick Sascha Merkle, Sonja Hudelmaier, Victor Le-Minh, Dominik Mertens, Claudio Schmid, Reto Ossola, Carsten Soenksen, Marlis Zeiler, Andrei Starikov, Edward Waterman, Petra Gutenbrunner, Nick DeGraan-Weber, Michelle English, François Griaud   +14 more
doaj   +1 more source

Amphiphilic block polymer-based self-assembly of high payload nanoparticles for efficient combinatorial chemo-photodynamic therapy

Drug Delivery, 2020
Combinatorial chemo-photodynamic therapy is regared as effective cancer therapy strategy, which could be realized via multiple nano-drug delivery system.
Qisan Ma, Yanna Zhao, Qingran Guan, Yuping Zhao, Huaizhen Zhang, Zhuang Ding, Qingpeng Wang, Yushu Wu, Min Liu, Jun Han   +9 more
doaj   +1 more source

Regulatory policy and the location of bio-pharmaceutical FDI in Europe [PDF]

This paper examines the relationship bewteen cross-country differences in drug price regulation and the location of biopharmaceutical Foreign Direct Investment (FDI) in Europe.
Megan Macgarvie, Pamina Koenig
core  

Biomedical Patents at the Supreme Court: A Path Forward [PDF]

, 2013
Although most would argue that software patents pose a bigger challenge, the U.S. Supreme Court has recently focused on biomedical patents. Two of the Court\u27s recent decisions scaling back such patents, Mayo v. Prometheus and AMP v.
Rai, Arti K.
core   +1 more source

Multiple Elements in Single Words [PDF]

, 2019
What\u27s the shortest word from which the names of 2 chemical elements can be spelled ...
Francis, Darryl
core   +1 more source

A Field Study on the Impacts of Implementing Concepts and Elements of Industry 4.0 in the Biopharmaceutical Sector

Journal of Open Innovation: Technology, Market and Complexity, 2020
This study proposes a field study, based on a literature review, about the applications and impacts of Industry 4.0 (I4.0) in the biopharmaceutical sector.
F. Silva, D. Resende, M. Amorim, M. Borges   +3 more
semanticscholar   +1 more source

Risk-Return Analysis of the Biopharmaceutical Industry as Compared to Other Industries

Frontiers in Pharmacology, 2018
Background: Profits in the biopharmaceutical industry have been scrutinized in social debate. However, drawing conclusions based on industry profitability only is inappropriate as such an analysis does not account for risks faced by investors. This study
Cedric Popa, Karel Holvoet, Tessa Van Montfort, Floris Groeneveld, Steven Simoens   +4 more
doaj   +1 more source

Technological Discontinuities and the Comparative Strategic Value of New Capabilites: Evidence from the Comparison of Small- and Large-Molecule Targeted Anti-Cancer Drug Discovery [PDF]

Traditional creative destruction theories distinguish disruptions as competence-destroying or competence-enhancing to incumbents’ capabilities, with the former case resulting in incumbents’ loss of competitive advantage in in-house R&D performance (even ...
M. Lourdes Sosa
core